FIELD: medicine.
SUBSTANCE: pharmaceutical composition for treating gastric and duodenal ulcers contains a proton pump inhibitor (PPI) in amount 0.05-25 wt %, and a prebiotic in amount 40-95 wt % specified in aliphatic alcohols, di-, tri-, oligo- or polysaccharides. A method of treating gastric and duodenal ulcers implies enteral administration of said pharmaceutical composition once a day for 14 days.
EFFECT: synergetic action of the proton pump inhibitor and prebiotic provides faster repair of gastric mucosal ulcers, effective stable eradication of Hpylori without using antibacterial therapy, the absence of side effects and recurrences.
14 cl, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING GASTROESOPHAGEAL REFLUX DISEASE | 2012 |
|
RU2501549C1 |
| METHOD FOR ANTI-HELICOBACTER THERAPY OF STOMACH AND DUODENUM | 2013 |
|
RU2537140C1 |
| PHARMACEUTICAL COMPOSITION FOR GASTRIC AND/OR DUODENAL ULCER | 2010 |
|
RU2448702C2 |
| METHOD FOR TREATING HELICOBACTER PYLORI-ASSOCIATED ULCEROUS GASTRIC AND DUODENAL DISEASE | 2006 |
|
RU2308949C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING RABEPRAZOLE AND METHOD FOR PRODUCING IT | 2014 |
|
RU2554735C1 |
| METHOD FOR IDENTIFYING HELICOBACTER PYLORI | 2000 |
|
RU2199743C2 |
| METHOD FOR HELICOBACTER PYLORI ERADICATION OF GASTRODUODENAL ZONE | 2014 |
|
RU2545687C1 |
| TREATMENT OF INFLAMMATORY GASTROINTESTINAL DISEASED ASSOCIATED WITH HELICOBACTER PYLORI | 2004 |
|
RU2278682C2 |
| COMPOSITION CONTAINING N-ACETYLCYSTEINE IN COMBINATION WITH PROBIOTIC BACTERIA ABLE TO RESTORE THEIR OWN STOMACH BARRIER EFFECT LOST PHARMA DURING PHARMACOLOGICAL TREATMENT OF GASTRIC HYPERACIDITY | 2012 |
|
RU2617952C2 |
| METHOD OF TREATING CHRONIC GASTRODUODENITIS ASSOCIATED WITH INFECTION CAUSED BY BACTERIA Helicobacter pylori IN ALLERGIC DISEASES | 2011 |
|
RU2472498C1 |
